Skip to main content

Table 1 Patient’s characteristics and outcome

From: Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma

Variable Total numbers Percentage
Patients with NLPHL 200 100
No data available 30 15
Malignancy related data available 170 65
Total families* of 170 patients 167
Male 130 76.5
Female 40 23.5
Median age 20.9 years Range (5–64)
Age < 21 86 50.6
Type and frequency of familial malignancies
 Family with no malignancy 77 46.1
 Families with malignancy 90 53.9
  Families with hematological only* 14 8.4
  Families with hematological + solid 17 10.2
  Families with solid cancers only 59 35.3
Total malignancies in family members 167
Total members with malignancy 162
Malignancy confirmed 73 43.7
 Confirmed among 35 hematological** 28 80
 Confirmed among 135 solid** 45 33.3
Malignancy unconfirmed 94 56.3
 Unconfirmed among 35 hematological** 7 20
 Unconfirmed among 135 solid** 90 66.66
First degree members 51 31.5
Second degree members 85 52.5
Third degree members 26 16
Common familial malignancy by groups*
 Hematological malignancies
  Non-Hodgkin lymphoma 16 9.6
  Hodgkin lymphoma 11 6.6
  Leukemia 8 4.8
Solid malignancies
 Gastrointestinal 36 21.6
 Female genital 13 7.8
 Breast 18 10.77
 Cancer not otherwise specified 19 11.4
 Lung / Head and Neck 17 10.2
 Others 27 16.17
  1. Percentages are counted for 170 available patients
  2. *6 patients from 3 families with NHLPH as the only malignancy are counted as 3 families
  3. **Percentages among the hematological and solid malignancies
  4. 5 Patient with 2 malignancies each are also adjusted accordingly